Congress designates lung cancer awareness month, spotlights screening gaps
H.Res. 960 — Expressing support for the designation of November 2025 as "National Lung Cancer Awareness Month" and expressing support for early detection and treatment of lung cancer. · Filed by Brendan Boyle (D-PA) · 1 cosponsor · Introduced Dec 18, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This resolution designates November 2025 as 'National Lung Cancer Awareness Month' and expresses congressional support for early detection, screening, and treatment of lung cancer. It does not create law or funding; it is a symbolic statement encouraging public awareness, education, and research efforts, with particular attention to disparities affecting Black men, women, veterans, and never-smokers.
Why we flagged it
This is a non-binding commemorative resolution expressing support for lung cancer awareness and early detection. It contains no regulatory, appropriations, or substantive legislative mechanism—only symbolic congressional endorsement of public health goals.
What the text implies
- Resolution's emphasis on screening access and geographic barriers may indirectly signal congressional interest in funding or policy changes to expand screening infrastructure, though no such mechanism is present in this text.
- Explicit mention of biomarker testing and 'cutting-edge diagnostics' access disparities may foreshadow future legislative interest in coverage or reimbursement policy for advanced lung cancer diagnostics.
- Focus on veteran screening (only 3% screened despite 1–2M eligible) may create political pressure for VA system reforms or screening mandates, though none are enacted here.
Who it affects
The resolution promotes public health awareness and early detection of a leading cause of cancer death, with explicit focus on underserved populations (minorities, veterans, never-smokers, women). It carries no direct cost to citizens and encourages screening access and stigma reduction.
Who stands to gain
- pharmaceutical companies (immunotherapy and targeted therapy manufacturers)
- diagnostic imaging and biomarker testing providers
- cancer treatment centers and oncology practices
Named in the bill
House Committee on Energy and Commerce, Mr. Boyle of Pennsylvania, Mr. Lawler, Veterans Affairs, FDA (implied regulatory context for diagnostics), CMS (implied coverage/reimbursement context)
Where it stands
1 cosponsor: 1 Republicans.
- Dec 18, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
How this was measured
Analysis — Quorum's AI read the full bill text on Jul 5, 2026; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
As of — page rendered 2026-10-20.
“Congress designates lung cancer awareness month, spotlights screening gaps” QuorumCivic. https://share.quorumcivic.app/bill/119/hres960 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.